Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy

Area of Science:

• Biomedical Research
• Cellular Biology
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder causing progressive muscle degeneration.
• Existing mouse models exhibit a milder phenotype compared to the established DMD rat model.
• The role of cellular senescence in DMD pathogenesis remains largely unexplored.

Purpose of the Study:

• To investigate the contribution of cellular senescence to DMD progression using a severe DMD rat model and patient samples.
• To identify specific cell types and molecular pathways involved in senescence during DMD.
• To evaluate the therapeutic potential of targeting senescence in DMD.

Main Methods:

• Utilized a DMD rat model with a more severe phenotype than mouse models.
• Assessed senescence markers (e.g., CDKN2A, p16, p19) in DMD rats and human DMD patient skeletal muscle.
• Performed genetic ablation of p16 in DMD rats.
• Administered the senolytic drug ABT263 to late-stage DMD rats.
• Conducted histological analysis and evaluated body weight, muscle strength, and muscle regeneration.

Main Results:

• Genetic ablation of p16 significantly restored body weight and muscle strength in DMD rats.
• Histological analysis revealed reduced fibrosis and adipose tissue infiltration, alongside enhanced muscle regeneration.
• Senolytic treatment with ABT263 improved outcomes even in late-stage DMD rats.
• Elevated senescence markers, including CDKN2A expression in satellite and mesenchymal progenitor cells, were observed in DMD patients.

Conclusions:

• Cellular senescence plays a critical role in the progression of Duchenne muscular dystrophy.
• Targeting senescence pathways, through genetic means or senolytic drugs, offers a promising therapeutic strategy for DMD.
• Senescence markers are present in key muscle progenitor cells in DMD patients, highlighting their involvement.